MA45692A - Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement - Google Patents

Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement

Info

Publication number
MA45692A
MA45692A MA045692A MA45692A MA45692A MA 45692 A MA45692 A MA 45692A MA 045692 A MA045692 A MA 045692A MA 45692 A MA45692 A MA 45692A MA 45692 A MA45692 A MA 45692A
Authority
MA
Morocco
Prior art keywords
aging
treatment
blood plasma
cognitive disorders
plasma fractions
Prior art date
Application number
MA045692A
Other languages
English (en)
Other versions
MA45692B1 (fr
Inventor
David Bell
Steven P Braithwaite
Vu Dang
Ian Gallager
Joe Mccracken
S Sakura Minami
Karoly Nikolich
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MA45692A publication Critical patent/MA45692A/fr
Publication of MA45692B1 publication Critical patent/MA45692B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA45692A 2016-08-18 2017-04-27 Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement MA45692B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24
PCT/US2017/029953 WO2018034712A1 (fr) 2016-08-18 2017-04-27 Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement

Publications (2)

Publication Number Publication Date
MA45692A true MA45692A (fr) 2019-05-22
MA45692B1 MA45692B1 (fr) 2021-10-29

Family

ID=61196950

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45692A MA45692B1 (fr) 2016-08-18 2017-04-27 Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement

Country Status (28)

Country Link
US (2) US20190321449A1 (fr)
EP (2) EP3995140A1 (fr)
JP (3) JP7316931B2 (fr)
KR (3) KR20240036720A (fr)
CN (2) CN115957309A (fr)
AU (3) AU2017312722B2 (fr)
BR (1) BR112019003172A2 (fr)
CA (1) CA3033051A1 (fr)
CL (1) CL2019000304A1 (fr)
CY (1) CY1124695T1 (fr)
DK (1) DK3484502T3 (fr)
ES (1) ES2899147T3 (fr)
HR (1) HRP20211628T1 (fr)
HU (1) HUE056294T2 (fr)
IL (2) IL264660B2 (fr)
LT (1) LT3484502T (fr)
MA (1) MA45692B1 (fr)
MD (1) MD3484502T2 (fr)
MX (1) MX2019001718A (fr)
NZ (1) NZ750885A (fr)
PL (1) PL3484502T3 (fr)
PT (1) PT3484502T (fr)
RS (1) RS62558B1 (fr)
SG (1) SG11201901273TA (fr)
SI (1) SI3484502T1 (fr)
UA (1) UA126232C2 (fr)
WO (1) WO2018034712A1 (fr)
ZA (1) ZA202004834B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299129A3 (fr) * 2017-04-26 2024-03-20 Alkahest, Inc. Schéma posologique pour le traitement de déficiences cognitives avec des produits de plasma sanguin
MX2020011114A (es) 2018-05-15 2021-01-29 Alkahest Inc Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
CN110787187B (zh) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用
WO2020018343A1 (fr) * 2018-07-20 2020-01-23 Alkahest, Inc. Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin
JP2022505915A (ja) 2018-10-26 2022-01-14 アルカヘスト，インコーポレイテッド 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用
CN110448686B (zh) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 铜蓝蛋白联合运铁蛋白的应用
WO2021062007A1 (fr) * 2019-09-25 2021-04-01 Cytegen Corp. Traitement de déficits mitochondriaux et de maladies liées à l'âge utilisant des produits sanguins
CA3151943A1 (fr) 2019-11-04 2021-05-14 Viktoria Kheifets Fraction de plasma sanguin a utiliser dans la regeneration musculaire
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
CN114746100A (zh) 2019-11-20 2022-07-12 万能溶剂有限公司 用于肝再生的血浆级分
CA3221177A1 (fr) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Modulateurs de benzodioxane de leucotriene a4 hydrolase (lta4h) pour la prevention et le traitement de maladies liees au vieillissement

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US20050143310A1 (en) * 2001-05-11 2005-06-30 Masaki Hirashima Novel remedies for neurodegenerative disease
US20070010435A1 (en) * 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
US20090297485A1 (en) * 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014182631A1 (fr) * 2013-05-06 2014-11-13 Baxter International Inc. Traitement de sous-populations atteintes de la maladie d'alzheimer avec de l'immunoglobuline g rassemblée
CN106163530A (zh) * 2013-12-09 2016-11-23 小利兰·斯坦福大学托管委员会 用于治疗衰老相关病症的方法和组合物
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP4299129A3 (fr) * 2017-04-26 2024-03-20 Alkahest, Inc. Schéma posologique pour le traitement de déficiences cognitives avec des produits de plasma sanguin

Also Published As

Publication number Publication date
JP7316931B2 (ja) 2023-07-28
LT3484502T (lt) 2021-12-10
PT3484502T (pt) 2021-11-18
ZA202004834B (en) 2022-07-27
HRP20211628T1 (hr) 2022-02-04
EP3484502B1 (fr) 2021-08-25
AU2020200181A1 (en) 2020-01-30
PL3484502T3 (pl) 2022-01-31
SI3484502T1 (sl) 2022-01-31
MA45692B1 (fr) 2021-10-29
SG11201901273TA (en) 2019-03-28
JP2019528269A (ja) 2019-10-10
EP3995140A1 (fr) 2022-05-11
KR20240036720A (ko) 2024-03-20
ES2899147T3 (es) 2022-03-10
CN109963582A (zh) 2019-07-02
IL264660B1 (en) 2023-11-01
MX2019001718A (es) 2019-09-13
CN115957309A (zh) 2023-04-14
JP2023156459A (ja) 2023-10-24
CA3033051A1 (fr) 2018-02-22
CY1124695T1 (el) 2022-07-22
RS62558B1 (sr) 2021-12-31
JP2022037124A (ja) 2022-03-08
JP7447069B2 (ja) 2024-03-11
DK3484502T3 (da) 2021-10-25
US20220152161A1 (en) 2022-05-19
AU2017312722A1 (en) 2019-03-14
IL264660B2 (en) 2024-03-01
WO2018034712A1 (fr) 2018-02-22
AU2017312722B2 (en) 2020-01-02
UA126232C2 (uk) 2022-09-07
KR20220107322A (ko) 2022-08-02
AU2021240142A1 (en) 2021-10-28
EP3484502A1 (fr) 2019-05-22
EP3484502A4 (fr) 2020-03-04
IL264660A (fr) 2019-04-30
HUE056294T2 (hu) 2022-02-28
NZ750885A (en) 2021-07-30
MD3484502T2 (ro) 2022-01-31
KR20190032614A (ko) 2019-03-27
AU2020200181B2 (en) 2021-07-22
BR112019003172A2 (pt) 2019-05-28
US20190321449A1 (en) 2019-10-24
IL304946A (en) 2023-10-01
CN109963582B (zh) 2022-12-27
CL2019000304A1 (es) 2019-05-31

Similar Documents

Publication Publication Date Title
MA45692A (fr) Fractions de plasma sanguin utilisées en tant que traitement de troubles cognitifs associés au vieillissement
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MA47095A (fr) Traitement du palais mou
DK3424534T3 (da) Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
CO2017002333A2 (es) Un artículo desechable que incluye por lo menos una región elástica unida
EA201691582A1 (ru) Новые фармацевтические препараты
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA47719A (fr) Esketamine pour le traitement de la dépression
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA42999A (fr) Polythérapie pour le traitement de malignités
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
MA43314A (fr) Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
DK3334412T3 (da) Farmaceutisk sammensætning, som omfatter elektrohydrodynamisk opnåede fibre, hvilken sammensætning har forøget opholdstid på påføringsstedet
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA52761A (fr) Schéma posologique destiné au traitement de troubles liés à la pi3k
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
SI3156798T1 (sl) Nov test za diagnosticiranje okužb s helminti
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
BR112016019246A2 (pt) processo paraa fabricação de hidroclorofluoro-olefinas